In last trading session, iSpecimen Inc. (NASDAQ:ISPC) saw 11.22 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $6.95 trading at $0.12 or 1.76% at ring of the bell on the day assigns it a market valuation of $65.40M. That closing price of ISPC’s stock is at a discount of -316.98% from its 52-week high price of $28.98 and is indicating a premium of 31.65% from its 52-week low price of $4.75. Taking a look at company’s average trading volume of 6.04 million if we extend that period to 3-months.
For iSpecimen Inc. (ISPC), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.22 in the current quarter.
iSpecimen Inc. (NASDAQ:ISPC) trade information
Upright in the green during last session for gaining 1.76%, in the last five days ISPC remained trading in the red while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $6.95 price level, adding 11.69% to its value on the day. iSpecimen Inc.’s shares saw a change of -11.01% in year-to-date performance and have moved -7.21% in past 5-day. iSpecimen Inc. (NASDAQ:ISPC) showed a performance of -44.58% in past 30-days.
Wall Street analysts have assigned a consensus price target of $20.00 to the stock, which implies a rise of 65.25% to its current value. Analysts have been projecting $20.00 as a low price target for the stock while placing it at a high target of $20.00. It follows that stock’s current price would drop -187.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -187.77% for stock’s current value.
iSpecimen Inc. (ISPC) estimates and forecasts
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $3.25 million for the same. And 2 analysts are in estimates of company making revenue of $3.59 million in the next quarter that will end on Mar 2022.
In 2022, company’s earnings growth rate is likely to be around 1.60% while estimates for its earnings growth in next 5 years are of 15.00%.
iSpecimen Inc. is more likely to be releasing its next quarterly report in February and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
iSpecimen Inc. (NASDAQ:ISPC)’s Major holders
Insiders are in possession of 31.18% of company’s total shares while institution are holding 10.81 percent of that, with stock having share float percentage of 15.71%. Investors also watch the number of corporate investors in a company very closely, which is 10.81% institutions for iSpecimen Inc. that are currently holding shares of the company. Bleichroeder LP is the top institutional holder at ISPC for having 0.62 million shares of worth $3.61 million. And as of Sep 29, 2021, it was holding 7.08% of the company’s outstanding shares.
The second largest institutional holder is Kepos Capital Lp, which was holding about 0.23 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 2.58% of outstanding shares, having a total worth of $1.31 million.
On the other hand, iShares Micro Cap ETF and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 5517.0 shares of worth $41432.0 or 0.06% of the total outstanding shares. The later fund manager was in possession of 2160.0 shares on Oct 30, 2021, making its stake of worth around $16221.0 in the company or a holder of 0.02% of company’s stock.